Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.91
+0.02 (0.25%)
Sep 16, 2026, 4:00 PM EDT - Market closed

Cartesian Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
239187461107--
Market Cap Growth
-4.92%-59.31%330.61%---
Enterprise Value
15657256---
Last Close Price
7.917.2117.9120.68--

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
162.0367.0311.844.12--
PB Ratio
--1.48-67.74-0.77--

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
105.3320.276.58---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
-0.51-0.10-2.06-0.080.400.18
Debt / EBITDA Ratio
----2.01-
Net Debt / Equity Ratio
0.670.8929.200.47-1.03-0.50
Net Debt / EBITDA Ratio
0.871.345.780.90-6.111.03
Net Debt / FCF Ratio
1.071.426.061.282.950.06
Asset Turnover
0.000.010.110.111.26-
Quick Ratio
7.198.459.291.265.766.38
Current Ratio
7.488.659.431.335.916.42
Return on Equity (ROE)
----70.21%-
Return on Assets (ROA)
-17.43%-14.82%-6.00%-19.75%10.35%-
Return on Capital Employed (ROCE)
-33.10%-30.80%-8.60%-31.40%10.30%-54.70%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-63.47%-69.50%-16.80%-205.34%--
FCF Yield
-32.85%-42.35%-7.11%-48.01%--
Buyback Yield / Dilution
-9.55%-49.63%-235.72%-6.33%-27.59%-
SEC Filings: 10-K · 10-Q